Compare Amgen, Inc. (AMGN) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs First Citizens BancShares Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while First Citizens BancShares Inc trades at $2,092.59 (market cap $23.94B). The key difference: Amgen, Inc. is far larger — about 8.2× First Citizens BancShares Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | FCNCA | |
|---|---|---|
Market Cap | $196.12B | $23.94B |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $2.20K |
52-Week Low | $271.18 | $1.64K |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
First Citizens BancShares (FCNCA) trades at $2,092.59, up 0.46% on the day, with a bearish technical signal but bullish moving averages. The company reported strong Q1 2026 earnings of $44.86 per share, beating estimates, and maintains a net income margin of 24.35%. Recent news highlights expansion in commercial banking and a planned rebrand of Silicon Valley Bank operations. Valuation ratios include a P/E of 12.07 and P/B of 1.2, suggesting reasonable pricing relative to earnings and book value.
The outlook for FCNCA is mixed, with solid profitability and earnings beats offset by margin pressure and credit risks. Analysts are predominantly neutral (82% hold), with a consensus price target of $2,320. Key risks include deposit volatility in tech-exposed segments and competitive pressures, while opportunities lie in continued operational execution and strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
